ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis

ZyVersa Therapeutics (NASDAQ:ZVSA) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ZyVersa Therapeutics and Keros Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0	0	1	0	3.00
Keros Therapeutics	0	6	8	0	2.57

ZyVersa Therapeutics presently has a consensus price target of $120.00, suggesting a potential upside of 16,007.38%. Keros Therapeutics has a consensus price target of $42.33, suggesting a potential upside of 277.30%. Given ZyVersa Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe ZyVersa Therapeutics is more favorable than Keros Therapeutics.

Profitability

This table compares ZyVersa Therapeutics and Keros Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-224.85%	-103.22%
Keros Therapeutics	-27,890.94%	-41.74%	-38.42%

Institutional & Insider Ownership

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 0.3% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ZyVersa Therapeutics and Keros Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$98.30 million	N/A	N/A
Keros Therapeutics	$3.55 million	128.20	-$152.99 million	($5.01)	-2.24

ZyVersa Therapeutics has higher earnings, but lower revenue than Keros Therapeutics.

Volatility and Risk

ZyVersa Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Summary

Keros Therapeutics beats ZyVersa Therapeutics on 7 of the 11 factors compared between the two stocks.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.